湖北远大永晟药业

Hubei Grand YongSheng Pharmaceutical is a specialized subsidiary of Grand Pharmaceutical Group, serving as a primary manufacturing hub for the group's emergency medicine and cardiovascular portfolios. Located in Xianning, Hubei, the company operates advanced GMP-certified facilities dedicated to the production of critical care injectables and active pharmaceutical ingredients (APIs). Its product line features essential medicines such as epinephrine, norepinephrine, and isoprenaline, which hold significant market shares in China's emergency clinical sector. As a key component of Grand Pharma's "Emergency Core" strategy, the company focuses on ensuring the supply of life-saving treatments for cardiac arrest, shock, and severe allergic reactions. Grand YongSheng integrates research, development, and large-scale production to support both domestic healthcare needs and international export markets.